WO2010070677A3 - A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof - Google Patents
A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof Download PDFInfo
- Publication number
- WO2010070677A3 WO2010070677A3 PCT/IN2009/000714 IN2009000714W WO2010070677A3 WO 2010070677 A3 WO2010070677 A3 WO 2010070677A3 IN 2009000714 W IN2009000714 W IN 2009000714W WO 2010070677 A3 WO2010070677 A3 WO 2010070677A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prasugrel
- pharmaceutically acceptable
- preparation
- acceptable salts
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
The present invention relates to processes for the preparation of prasugrel and its pharmaceutically acceptable salts, including novel crystalline forms of prasugrel hydrochloride, and pharmaceutical compositions thereof. The present invention also relates to solid state properties of prasugrel or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2609/MUM/2008 | 2008-12-15 | ||
IN2609MU2008 | 2008-12-15 | ||
IN343/MUM/2009 | 2009-02-17 | ||
IN343MU2009 | 2009-02-17 | ||
IN1248MU2009 | 2009-05-14 | ||
IN1248/MUM/2009 | 2009-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010070677A2 WO2010070677A2 (en) | 2010-06-24 |
WO2010070677A3 true WO2010070677A3 (en) | 2011-02-24 |
Family
ID=42269188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2009/000714 WO2010070677A2 (en) | 2008-12-15 | 2009-12-09 | A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010070677A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2469883A (en) * | 2009-04-30 | 2010-11-03 | Sandoz Ag | Novel crystalline form of Prasugrel hydrogensulphate |
DE102009036646A1 (en) * | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in non-crystalline form and pharmaceutical composition thereof |
ES2533681T3 (en) | 2010-04-08 | 2015-04-14 | Teva Pharmaceutical Industries Ltd. | Crystal forms of Prasugrel salts |
WO2012023145A2 (en) * | 2010-08-18 | 2012-02-23 | Hetero Research Foundation | Prasugrel hydrochloride crystalline particles |
CN102838618A (en) | 2011-06-22 | 2012-12-26 | 广东东阳光药业有限公司 | Method for preparing prasugrel, and prasugrel hydrochloride novel crystal forms |
US8603537B2 (en) | 2012-04-02 | 2013-12-10 | Egis Pharmaceuticals Plc | Prasugrel containing quickly released stable oral pharmaceutical compositions |
PL402028A1 (en) | 2012-12-12 | 2014-06-23 | Instytut Farmaceutyczny | Method for preparing polymorph B form of Prasugrel hydrochloride in pharmaceutical grade |
CN103610674B (en) * | 2013-12-09 | 2015-01-07 | 海南灵康制药有限公司 | Solid preparation containing micronized prasugrel |
CN117619352B (en) * | 2024-01-26 | 2024-04-09 | 中国科学院合肥物质科学研究院 | Degradation agent of perfluoro compound and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0542411A2 (en) * | 1991-09-09 | 1993-05-19 | Sankyo Company Limited | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
EP0785205A1 (en) * | 1994-10-07 | 1997-07-23 | Ube Industries, Ltd. | 2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same |
WO2007114526A1 (en) * | 2006-04-06 | 2007-10-11 | Daiichi Sankyo Company, Limited | Process for producing high-purity prasugrel and acid addition salt thereof |
-
2009
- 2009-12-09 WO PCT/IN2009/000714 patent/WO2010070677A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0542411A2 (en) * | 1991-09-09 | 1993-05-19 | Sankyo Company Limited | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
EP0785205A1 (en) * | 1994-10-07 | 1997-07-23 | Ube Industries, Ltd. | 2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same |
WO2007114526A1 (en) * | 2006-04-06 | 2007-10-11 | Daiichi Sankyo Company, Limited | Process for producing high-purity prasugrel and acid addition salt thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2010070677A2 (en) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010070677A3 (en) | A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof | |
WO2009066326A3 (en) | Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
WO2011042918A3 (en) | Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof | |
WO2009084024A3 (en) | A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof | |
WO2009062044A3 (en) | Processes for the preparation of prasugrel, and its salts and polymorphs | |
WO2007141283A3 (en) | Salts and crystalline salt forms of an 2-indolinone derivative | |
WO2009085990A3 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
WO2010001257A3 (en) | Novel solid state forms of laquinimod and its sodium salt | |
WO2011048604A3 (en) | Processes for the preparation of darunavir and the amorphous form thereof | |
WO2012070062A3 (en) | Novel polymorph of nilotinib hydrochloride | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2011157722A3 (en) | Solid ivabradine-containing composition | |
WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
WO2010070449A3 (en) | Highly pure laquinimod or a pharmaceutically acceptable salt thereof | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
WO2008001201A3 (en) | Pharmaceutical compositions of clopidogrel | |
IN2012DN04868A (en) | ||
WO2010129636A3 (en) | Lenalidomide polymorph | |
WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
WO2010079045A3 (en) | Crystalline salt forms of flibanserine | |
WO2011008666A3 (en) | 3-phenoxymethylpyrrolidine compounds | |
WO2010046932A3 (en) | Extended release pharmaceutical composition of minocycline and process thereof | |
WO2009097515A3 (en) | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09833086 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09833086 Country of ref document: EP Kind code of ref document: A2 |